Measurement of Circulating Cell-free DNA (cfDNA) for Diagnosis and Prognosis of Various Diseases and Evaluation of Tissue Damage
- Conditions
- Correlation of cFDNA During CPB to Laboratories SIRS Parameters and Clinical Outcomes
- Registration Number
- NCT05094960
- Lead Sponsor
- Soroka University Medical Center
- Brief Summary
To characterize the changes in circulating cell-free DNA (cfDNA) levels during cardiopulmonary bypass (CPB) and to access their association with outcomes compared to standard scores.
- Detailed Description
In a prospective study, the investigators enrolled seventy-one consecutive patients undergoing non-emergent coronary artery bypass grafting. Blood was drawn at baseline, after 20 and 40 minutes on CPB, after cross-clamp removal, and 30 minutes after chest closure. cfDNA was measured in sera by fluorescent method.
The investigators hypothesize that cfDNA measured by will reflect the magnitude of inflammation induced by CPB. Thus, these measurements could serve for the real-time prognosis of patients undergoing cardiac surgery. The investigators correlate cFDNA to laboratories and clinical outcomes.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 71
- Elective coronary artery bypass grafting surgery
- Age < 18
- Non elective surgery
- other than CABG surgery
- Redo CABG
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method prolong LOS-length of stay > 18 hours after the surgery intensive care unit length of stay
Mortality short term - 30day; long term > 1year Mortality
- Secondary Outcome Measures
Name Time Method Neutrophil-NETosis 2 hours after the surgery Neutrophil extracellular traps (NETs) released from activated neutrophils that undergo NETosis.